📋 Clinical Overview

Nartograstim is a recombinant human granulocyte colony-stimulating factor (rhG-CSF) analog, specifically a pegylated form of filgrastim. It is a long-acting hematopoietic growth factor that stimulates the proliferation, differentiation, and activation of neutrophils. The 300 mcg dose is a standard single-administration vial/pre-filled syringe primarily used for prophylaxis of chemotherapy-induced neutropenia. Its pegylation significantly extends its half-life compared to short-acting G-CSFs, allowing for once-per-chemotherapy-cycle dosing.

💊 Dosage & Administration

Adult: 300 mcg administered as a single subcutaneous injection once per chemotherapy cycle. Administer at least 24 hours after and more than 24 hours before the administration of chemotherapy.

Note: For subcutaneous use only. Administer in the upper arm, abdomen (except 2-inch area around navel), or thigh. Rotate injection sites. Use pre-filled syringe or reconstituted vial as per instructions. Do not shake vigorously. Allow to reach room temperature for 30 mins before injection. Inspect for particulate matter or discoloration.

⚠️ Contraindications

Known hypersensitivity to Nartograstim, Filgrastim, Pegfilgrastim, or any component of the formulation (e.g., polysorbate).
Simultaneous administration with chemotherapy or radiotherapy (must be administered at least 24 hours before or 24 hours after chemotherapy).
Patients with myeloid malignancies or myelodysplastic syndrome (MDS) due to risk of disease progression.

🔬 Mechanism of Action

Nartograstim binds to specific cell surface receptors (G-CSFR) on hematopoietic progenitor cells and mature neutrophils. This binding activates intracellular signaling pathways (primarily JAK/STAT, MAPK) leading to proliferation, differentiation, and functional activation of neutrophil lineage cells. It also promotes the release of mature neutrophils from the bone marrow into the bloodstream.

🤕 Side Effects

Bone pain (mild to moderate, in lower back, pelvis, long bones)
Headache
Injection site reactions (pain, erythema, swelling)
Fatigue
Nausea
Musculoskeletal pain

🤰 Special Populations

Pregnancy: Category C. Animal studies show reproductive toxicity. Use only if potential benefit justifies potential fetal risk. No adequate, well-controlled studies in pregnant women. Should be prescribed by an oncologist after careful consideration.

Driving: Generally safe. However, patients should be cautioned about potential dizziness, fatigue, or bone pain which may impair ability to drive or operate machinery.

🔄 Drug Interactions

Lithium	May potentiate the release of neutrophils; monitor for excessive leukocytosis.	Moderate
Chemotherapeutic Agents (e.g., 5-FU, Anthracyclines, Alkylating agents)	Concurrent administration can increase sensitivity of myeloid cells to chemotherapy. MUST be timed (≥24 hr gap).	High
Corticosteroids	May potentiate myeloproliferative effects; clinical significance unclear.	Low
Other Myelosuppressive Drugs	Additive risk of cytopenias if not timed correctly.	Moderate

Grastofil